IntroductionMammalian‐based expression systems make up more than 60% of the biopharmaceutical market, with sales exceeding 140 billion dollars in 2013. Among these systems, Chinese hamster ovary (CHO) cells account for the majority of approved products and are state of the art for the production of recombinant protein therapeutics. Large and complex‐structured biologics require human‐like post‐translational modifications in order to be non‐immunogenic and functional, a feature that is adequately fulfilled by CHO cells. On the downside, CHO cells, like all rapidly growing and immortalized cell lines, are genomically unstable, intraclonally heterogeneous, and frequently undergo genotypic variations. These lead to phenotypic instability and hence problems with respect to process reproducibility or production instability. As a consequence of such genotypic drifts, CHO cells are quasi‐diploid with a chromosome number that diverges from that of the primary Chinese hamster and with different karyotypes and modal chromosome numbers for each cell line analyzed.To overcome the heterogenic nature of CHO cells, a lot of effort is put into clone and cell line development in order to obtain a clonal cell line with advantageous growth, productivity, and stable properties. The requirement for clonality is based on the assumption that subclones are phenotypically and genetically homogenous and
Biotechnology Journal – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera